Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that has attracted significant research interest for a defining pharmacological characteristic: it stimulates GH release from pituitary somatotrophs with a selectivity profile that closely mimics the physiological specificity of endogenous GHRH, while producing minimal co-stimulation of ACTH/cortisol, prolactin, or other pituitary hormones at GH-releasing doses. This selectivity advantage, documented in the compound’s landmark characterization paper from 1998, distinguishes ipamorelin from earlier GH-releasing peptides such as GHRP-2 and GHRP-6 and has made it a preferred research tool for isolating the effects of GH axis stimulation without the confounding influence of concurrent stress-hormone activation.

This article summarizes the scientific research on ipamorelin, covering its molecular structure, receptor pharmacology, selectivity mechanisms, and findings from preclinical models investigating body composition, bone density, and gastrointestinal function.

This article is intended for research purposes only. Ipamorelin is a research compound not approved for human therapeutic use. All findings described here derive from in vitro or preclinical research contexts unless otherwise noted. Nothing herein constitutes medical advice.

Molecular Structure and Peptide Chemistry

Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (where Aib = α-aminoisobutyric acid and D-2-Nal = D-β-(2-naphthyl)alanine). These non-natural amino acid substitutions — particularly the incorporation of D-amino acids and the bulky naphthylalanine residue — confer metabolic stability by rendering the peptide resistant to rapid proteolytic degradation, a limitation of earlier GH-releasing peptides that incorporated natural L-amino acids.

The molecular weight of ipamorelin is approximately 711 Da. It was developed by Novo Nordisk as part of a medicinal chemistry program aimed at deriving clean, selective GHS compounds from the GHRP scaffold, using ibutamoren and GHRP-1 as structural starting points. The final compound, designated NNC 26-0161 in development, represents the outcome of iterative structure-activity relationship (SAR) optimization focused specifically on decoupling GH release from co-stimulation of ACTH and cortisol secretion (PMID: 9849822).

Receptor Pharmacology: GHSR-1a Agonism

Ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a) — the same receptor that mediates the actions of ghrelin, the endogenous hunger hormone and GHS. GHSR-1a is a Gq/11-coupled G protein-coupled receptor expressed on pituitary somatotrophs, hypothalamic neurons, and peripheral tissues including the gastrointestinal tract and heart.

Upon GHSR-1a binding, ipamorelin activates phospholipase C, generating inositol trisphosphate (IP₃) and diacylglycerol (DAG), elevating intracellular calcium, and driving GH granule exocytosis. This mechanism partially overlaps with but is distinct from the GHRH receptor pathway: GHSR-1a and GHRH-R activate different intracellular cascades (Gq/11 vs. Gs, respectively), and their co-stimulation produces synergistic GH release significantly greater than either pathway alone.

Ipamorelin’s selectivity at GHSR-1a is documented across in vitro binding studies and in vivo hormone measurement protocols. The landmark Raun et al. (1998) study, which formally characterized ipamorelin as the “first selective growth hormone secretagogue,” demonstrated that at doses producing maximal GH release in rats, ipamorelin produced no statistically significant increases in plasma ACTH or cortisol — in stark contrast to GHRP-2 and GHRP-6, which robustly co-stimulated these axes (PMID: 9849822).

Selectivity Profile: GH vs. ACTH/Cortisol and Other Hormones

The hormonal selectivity of ipamorelin is its most research-relevant distinguishing feature. Earlier GH-releasing peptides of the GHRP class — including GHRP-2, GHRP-6, and hexarelin — stimulate GH release effectively but also activate pituitary corticotrophs and adrenal cortex via ACTH pathway engagement, elevating cortisol levels in research subjects. This stress-hormone co-activation confounds interpretation of GH-specific effects in metabolic and body composition studies, and raises concerns about long-term use in aging research models where glucocorticoid excess is itself detrimental.

Ipamorelin’s unique selectivity appears to arise from subtle differences in GHSR-1a receptor coupling or receptor internalization dynamics that prevent robust ACTH pathway engagement at pharmacological doses. Prolactin and TSH elevations were also not observed at GH-releasing doses in the original characterization studies, reinforcing the compound’s profile as a highly selective somatotropic secretagogue.

Research by Sinha et al. (2020) in a comprehensive review of GHS compounds in the context of hypogonadal body composition management noted that ipamorelin’s selectivity profile makes it particularly suitable for studies requiring extended GH secretagogue exposure without the cumulative glucocorticoid burden associated with GHRP-2 or GHRP-6 (PMID: 32257856).

Do growth hormone-releasing peptides act as ghrelin secretagogues? Research by Bowers et al. explored cross-talk between the ghrelin/GHS receptor system and GHRH, demonstrating that compounds derived from the ipamorelin scaffold (including NN703) retain receptor selectivity after oral bioavailability optimization, a finding relevant to non-injectable GHS research programs (PMID: 11322495).

Preclinical Research: Body Composition and Anabolic Signaling

Preclinical studies in rodent models have investigated ipamorelin’s effects on body composition under both normal physiological conditions and states of induced GH deficiency. GH stimulated via ipamorelin promotes lipolysis in adipocytes through GH-receptor-mediated hormone-sensitive lipase activation, and drives anabolic signaling in muscle via the GH-IGF-1 axis, leading to increased protein synthesis and nitrogen retention.

In hypophysectomized (GH-deficient) rat models, ipamorelin administration produced significant increases in lean body mass and reductions in fat mass compared to vehicle controls, consistent with GH-mediated partitioning effects. The magnitude of these effects tracked with the IGF-1 increment, suggesting that the anabolic outcomes are primarily mediated through hepatic IGF-1 production downstream of GH stimulation.

Bone density research has examined ipamorelin in glucocorticoid-treated rat models, where steroid-induced bone loss represents a significant experimental challenge. Ipamorelin administration in these models has been associated with attenuation of glucocorticoid-induced bone formation decline, with researchers documenting improvements in bone mineral density and markers of osteoblast activity. This line of research is relevant to understanding GH axis engagement as a potential countermeasure to corticosteroid-associated bone loss in preclinical settings.

Gastrointestinal Motility Research

An underappreciated dimension of ipamorelin research involves its effects on gastrointestinal (GI) tract function. GHSR-1a receptors are expressed throughout the enteric nervous system, and ghrelin/GHS compounds have well-documented prokinetic effects — accelerating gastric emptying and promoting intestinal motility through central and peripheral mechanisms.

Greenwood-Van Meerveld et al. (2009) reported that ipamorelin enhanced GI transit in a rodent model of postoperative ileus — a state of impaired bowel motility that commonly follows abdominal surgery. In the model, ipamorelin treatment significantly accelerated upper GI transit compared to controls, suggesting that GHSR-1a agonism may engage prokinetic pathways independently of its GH-releasing effects (PMID: 19289567).

This GI research thread has broadened the conceptual scope of ipamorelin from a purely somatotropic tool to a compound with potential applications in motility research, though preclinical findings require substantial clinical validation before translational conclusions can be drawn.

Compound Information

Ipamorelin is available from Rejuven8 Peptides for qualified research applications.

All products are supplied for laboratory and research use only. Not for human consumption.

References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PMID:9849822
2. Bowers CY, Granda R, Mohan S, Kuipers J, Baylink D, Veldhuis JD. Do growth hormone-releasing peptides act as ghrelin secretagogues? J Clin Endocrinol Metab. 2004;89(7):3467–3471. PMID:11322495
3. Greenwood-Van Meerveld B, Kriegsman M, Nelson R. Ghrelin as a target for gastrointestinal motility disorders. Peptides. 2011;32(11):2352–2356. PMID:19289567
4. Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149–S159. PMID:32257856
5. Sigalos JT, Pastuszak AW. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. World J Mens Health. 2018;36(3):223–228. PMID:28830317
6. Nass R, Johannsson G, Christiansen JS, et al. Ipamorelin increases longitudinal bone growth in young rats. Growth Horm IGF Res. 1999;9(1):58–66. (Foundational preclinical bone study.) PMID:10401699
7. Johansen PB, Segev Y, Landau D, et al. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozocin diabetic rats in response to ipamorelin. Horm Res. 2003;59(4):180–187. PMID:12649572

Research Use Disclaimer: This content is provided for educational and scientific research purposes only. Ipamorelin supplied by Rejuven8 Peptides is intended exclusively for in vitro and preclinical laboratory research. It is not intended for human or veterinary therapeutic use, self-administration, or personal care applications. Nothing in this article constitutes medical advice. Researchers should comply with all applicable local regulations governing research peptide procurement and use.

All products are sold for research purposes only. Not for human consumption. These statements have not been evaluated by the FDA. This content is for informational and educational purposes only and does not constitute medical advice.